14 completed, 1 not yet recruiting. 15 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 14, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 2 |
Follow Human Immunodeficiency Virus (HIV): new trials by email Literature Review of Human Immunodeficiency Virus (HIV) trials Research Report on Human Immunodeficiency Virus (HIV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019) MK-8527, Rifampin - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 14 | 2026-09-01 | 2026-08-03 |
| A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE) MK-8527, LNG/EE - Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis | Phase 1 | Completed | Merck Sharp & Dohme LLC | 14 | 2023-08-14 | 2025-01-20 |
| Safety, Tolerability, and Immunogenicity of ALFQ in a HIV Vaccine Containing A244 and B.65321 in Healthy Adults A244, B.63521, 50μg ALFQ - Human Immunodeficiency Virus (HIV), AIDS Virus | Phase 1 | Completed | U.S. Army Medical Research and Development Command | 65 | 2022-09-08 | 2026-02-09 |
| A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children DRV/COBI FDC - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Janssen Research & Development, LLC | 15 | 2022-08-03 | 2023-09-14 |
| Study to Assess Adverse Events and How Intravenous (IV) or Subcutaneous (SC) ABBV-382 Moves Through the Body of Adult Participants With Human Immuno-Deficiency Virus (HIV-1) ABBV-382, Placebo for ABBV-382 - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | AbbVie | 54 | 2021-04-16 | 2024-03-04 |
| Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV) Budigalimab, Placebo - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | AbbVie | 33 | 2021-03-15 | 2022-10-17 |
| A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1 ABBV-181, Placebo - Human Immunodeficiency Virus (HIV), HIV Infection | Phase 1 | Completed | AbbVie | 41 | 2020-01-30 | 2023-03-09 |
| Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults VRC-HIVRGP096-00-VP, Alum Adjuvant - Human Immunodeficiency Virus Prevention, Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 16 | 2019-03-07 | 2021-08-12 |
| The Effect of Ixazomib on the Latent HIV Reservoir Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG - Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | Completed | Mayo Clinic | 17 | 2017-03-20 | 2022-01-06 |
| 3BNC117 and 10-1074 in HIV-infected Individuals 3BNC117, 10-1074, Analytical treatment interruption - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Rockefeller University | 34 | 2016-06-01 | 2018-08-21 |
| A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients ZFN Modified CD4+ T Cells, Cyclophosphamide - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | University of Pennsylvania | 14 | 2015-04-01 | 2019-04-10 |
| Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART SB-728mR-T, Cyclophosphamide - Human Immunodeficiency Virus (HIV) | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 8 | 2014-08-01 | 2021-03-19 |
| A Study To Investigate The Clearance Of PF-04776548 From The Body Following A Very Low (Micro) Dose Of The Compound Using A Low Level Of Radiotracer To Help Quantify Expected Low Concentrations Of PF-04776548 In The Body PF-04776548 - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Pfizer | 10 | 2010-01-01 | 2010-04-02 |
| SPL7013 Gel - Male Tolerance Study 3% w/w SPL7013 Gel (VivaGel™) - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Starpharma Pty Ltd | 36 | 2006-08-01 | 2008-01-16 |
| A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) MDX-010 - Human Immunodeficiency Virus (HIV) | Phase 1 | Completed | Bristol-Myers Squibb | 24 | 2003-04-21 | 2018-01-23 |
Acquired Immunodeficiency Syndrome (15) · HIV Infections (1)
Blood-Borne Infections (15) · Communicable Diseases (15) · Genital Diseases (15) · Immune System Diseases (15) · Immunologic Deficiency Syndromes (15) · Infections (15) · Lentivirus Infections (15) · RNA Virus Infections (15) · Retroviridae Infections (15) · Sexually Transmitted Diseases (15) · Sexually Transmitted Diseases, Viral (15) · Slow Virus Diseases (15) · Urogenital Diseases (15) · Virus Diseases (15) · HIV Infections (14)
Cyclophosphamide (2) · budigalimab (2) · 3BNC117 antibody (1) · Aluminum Hydroxide (1) · Antibodies, Monoclonal (1) · Ethinyl Estradiol-Norgestrel Combination (1) · Ipilimumab (1) · Rifampin (1) · aluminum sulfate (1) · astodrimer (1) · ixazomib (1)
AbbVie (3) · Merck Sharp & Dohme LLC (2) · Bristol-Myers Squibb (1) · Janssen Research & Development, LLC (1) · Mayo Clinic (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1) · Rockefeller University (1) · Sangamo Therapeutics (1) · Starpharma Pty Ltd (1) · U.S. Army Medical Research and Development Command (1) · University of Pennsylvania (1)
United States (12) · Puerto Rico (3) · Australia (2) · Canada (1) · Germany (1) · South Africa (1) · Spain (1) · United Kingdom (1)
Brennan Cebula, MD (1) · Marcus Chen, MD, PhD (1) · Marina Caskey, MD (1) · Martin R Gaudinski, M.D. (1) · Nathan Cummins, MD (1)
PMID 29879143, PMID 33571163, PMID 35783486, PMID 41094034
2019 (1), U01AI104400 (1)